Search

everythinglearnresearchcommunity

for

Search:↓

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Baricitinib is effective as a treatment for severe hair loss.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Baricitinib is a safe and effective treatment for severe alopecia areata.

Identical p53 gene mutations in different cancers suggest the need for careful treatment.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

A reliable method was developed to measure Minoxidil and Tofacitinib in gel for hair loss treatment.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Peficitinib can turn human fibroblasts into cells that help grow hair.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

M30 is a promising treatment for preventing hair loss during chemotherapy.

The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.

Upadacitinib may cause hair loss.

Tofacitinib is effective and safe for treating alopecia areata.

Baricitinib is effective and safe for treating severe alopecia areata.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.